Skip to Content

New Drug Approvals Archive - March 2009

March 2009

Edluar (zolpidem) Sublingual Tablets - formerly Sublinox

Date of Approval: March 13, 2009
Company: Orexo and Meda AB
Treatment for: Insomnia

Edluar (formerly Sublinox) is a fast-acting sublingual tablet formulation of the widely used drug zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Read more: Edluar (zolpidem) FDA Approval History

Symbyax (fluoxetine and olanzapine)

New Indication Approved: March 19, 2009

Afinitor (everolimus) Tablets

Date of Approval: March 30, 2009
Company: Novartis AG
Treatment for: Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma

Afinitor (everolimus) is an oral once-daily inhibitor of mTOR indicated for the treatment of patients with advanced HR+, HER2- breast cancer; progressive neuroendocrine tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis.

Read more: Afinitor (everolimus) FDA Approval History

Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed)

Date of Approval: March 30, 2009
Company: Intercell AG
Treatment for: Japanese Encephalitis Virus Prophylaxis

Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) is a purified, inactivated product for active immunization against viral infections of Japanese Encephalitis.

Read more: Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) FDA Approval History

Afinitor (everolimus)

New Indication Approved: October 29, 2010

Read more: Afinitor (everolimus) FDA Approval History

New Drug Approvals Archive